Clinic
Planned Parenthood of Greater New York INC
Planned Parenthood of Greater New York INC was paid $78.25M by Medicaid between Jan 2018 and Dec 2024, across 129 billing codes. Its largest line is 59840, — 23% of everything it billed.
33Billing provider infoPLANNED PARENTHOOD OF GREATER NEW YORK INC
NEW YORK, NY 10012
NEW YORK, NY 10012
33aNPI1417959701assigned 06/01/2005
33bProvider typeAmbulatory Family Planning Facility
28Total paid$78.25M
24GClaims946,099
24DCodes billed129
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Family Planning Facility providers in New York
Rank by total paid#1 of 7
Median peer was paid$9.13M
This provider vs. median8.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,740 | $1.54M | |
| 2019 | 58,152 | $5.90M | |
| 2020 | 152,739 | $14.66M | |
| 2021 | 156,935 | $15.04M | |
| 2022 | 139,022 | $13.87M | |
| 2023 | 228,970 | $14.71M | |
| 2024incomplete | 193,541 | $12.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 59840 | 23% | 26,310 | 26,000 | $18.19M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 68,541 | 59,890 | $9.41M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.8% | 37,885 | 35,816 | $6.09M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 6.2% | 45,766 | 42,444 | $4.87M |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 5.6% | 9,137 | 9,059 | $4.40M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 4.8% | 25,187 | 23,834 | $3.78M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.8% | 19,700 | 19,579 | $2.95M |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 3.7% | 27,199 | 24,940 | $2.87M |
| 11981 | 2.6% | 7,732 | 7,517 | $2.00M | |
| 11982 | 2.6% | 6,617 | 6,504 | $2.00M | |
| J7300 | Intrauterine copper contraceptive (paragard) | 2.5% | 4,600 | 4,551 | $1.98M |
| S0190 | Mifepristone, oral, 200 mg | 2.3% | 27,640 | 27,429 | $1.79M |
117 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.2% | 11,624 | $1.71M |
| 58300 | 2.1% | 11,478 | $1.64M | |
| 59841 | 2.0% | 2,003 | $1.60M | |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.8% | 9,609 | $1.38M |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | 1.2% | 3,261 | $969K |
| 58301 | 1.2% | 6,313 | $948K | |
| 59200 | 1.2% | 1,543 | $920K | |
| 86703 | <1% | 56,563 | $748K | |
| 36416 | <1% | 30,307 | $597K | |
| 88304 | <1% | 11,321 | $503K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 25,898 | $478K |
| 90651 | <1% | 2,674 | $468K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,280 | $436K |
| A4649 | Surgical supply; miscellaneous | <1% | 945 | $435K |
| 11983 | <1% | 1,098 | $392K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,461 | $390K |
| 57454 | <1% | 771 | $387K | |
| 99385 | <1% | 2,538 | $375K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,422 | $358K |
| J7301 | Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg | <1% | 908 | $316K |
| 76857 | <1% | 2,341 | $309K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,980 | $297K |
| 86901 | <1% | 10,057 | $286K | |
| J7296 | Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg | <1% | 636 | $240K |
| 99201 | <1% | 1,504 | $226K | |
| 81025 | <1% | 58,584 | $179K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,680 | $131K |
| 99051 | <1% | 11,136 | $125K | |
| 99401 | <1% | 2,922 | $119K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 45,718 | $111K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 385 | $97K |
| 99386 | <1% | 653 | $92K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 45,799 | $72K |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 27,715 | $70K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,501 | $70K |
| 76998 | <1% | 477 | $67K | |
| 99441 | <1% | 422 | $57K | |
| 99442 | <1% | 336 | $45K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,317 | $41K |
| H0049 | Alcohol and/or drug screening | <1% | 1,807 | $29K |
| 87806 | <1% | 2,603 | $22K | |
| 64435 | <1% | 1,012 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 113 | $17K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,571 | $16K |
| 99406 | <1% | 369 | $16K | |
| S4993 | Contraceptive pills for birth control | <1% | 4,379 | $13K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 116 | $10K |
| 88142 | <1% | 569 | $10K | |
| 59812 | <1% | 12 | $9K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 42 | $8K |
| 87210 | <1% | 18,600 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,054 | $7K |
| 85018 | <1% | 13,467 | $6K | |
| 99443 | <1% | 41 | $6K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 9,790 | $5K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 7,926 | $4K |
| 85013 | <1% | 4,017 | $4K | |
| 99000 | <1% | 287 | $4K | |
| J2788 | Injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.) | <1% | 151 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,223 | $3K |
| 81002 | <1% | 5,350 | $3K | |
| 96160 | <1% | 147 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 12 | $2K |
| 90385 | <1% | 780 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,401 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 329 | $1K |
| 86803 | <1% | 6,087 | $1K | |
| 99152 | <1% | 1,248 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,642 | $1K |
| 88300 | <1% | 8,099 | $1K | |
| 88174 | <1% | 47 | $887.87 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 139 | $817.80 |
| 86696 | <1% | 643 | $641.90 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 750 | $637.29 |
| 86780 | <1% | 8,799 | $629.93 | |
| 96127 | <1% | 1,063 | $617.55 | |
| 90674 | <1% | 32 | $507.81 | |
| 87660 | <1% | 795 | $489.13 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,306 | $479.55 |
| 87510 | <1% | 806 | $455.11 | |
| 86592 | <1% | 988 | $420.28 | |
| 87480 | <1% | 808 | $416.51 | |
| 81005 | <1% | 1,838 | $389.86 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,463 | $389.28 |
| 83986 | <1% | 6,747 | $364.70 | |
| 87529 | <1% | 473 | $356.21 | |
| 87563 | <1% | 213 | $339.95 | |
| 84702 | <1% | 3,608 | $270.02 | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 14 | $187.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 540 | $163.60 |
| 86695 | <1% | 268 | $124.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 880 | $115.04 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 2,038 | $100.57 |
| 99072 | <1% | 3,994 | $98.00 | |
| 81003 | <1% | 575 | $86.11 | |
| A4550 | Surgical trays | <1% | 1,191 | $82.50 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 251 | $55.00 |
| 86706 | <1% | 137 | $38.38 | |
| 99070 | <1% | 243 | $15.75 | |
| 84520 | <1% | 77 | $4.12 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 39 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 17 | $0.00 |
| 87521 | Neg quan hep c or qual rna | 0% | 14 | $0.00 |
| 99080 | 0% | 1,561 | $0.00 | |
| S5000 | Prescription drug, generic | 0% | 66 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 24 | $0.00 |
| 84132 | 0% | 885 | $-72.32 | |
| 86704 | 0% | 217 | $-72.50 | |
| 83001 | 0% | 24 | $-72.68 | |
| 84403 | 0% | 1,656 | $-102.52 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 2,705 | $-139.46 |
| 86593 | 0% | 592 | $-163.56 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 448 | $-236.93 |
| 84146 | 0% | 278 | $-257.89 | |
| 82565 | 0% | 1,283 | $-271.26 | |
| 87340 | 0% | 908 | $-287.41 | |
| 82670 | 0% | 918 | $-632.92 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMESSINA, ROSALBA (CHIEF OPERATING OFFICER)